EpiCast Report: Chronic Kidney Disease – Epidemiology Forecast to 2026

Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time (NIH, 2010). As the disease progresses, the symptoms worsen, eventually leading to kidney failure (NIH, 2010). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease, Improving Global Outcomes (KDIGO) classification system is considered the standard for GFR measurement and diagnosis of CKD.

GlobalData epidemiologists provide a 10-year epidemiological forecast for the total prevalent cases (including both diagnosed and undiagnosed cases) of CKD Stages I–IV by age and sex, the total prevalent cases of CKD by stage, the diagnosed prevalent cases of CKD Stages I–V, and the diagnosed prevalent cases of CKD by stage.

In the 7MM, GlobalData epidemiologists forecast the diagnosed prevalent cases of CKD, Stages I–V, to increase from 25,775,828 cases in 2016 to 28,325,839 cases in 2026, at an Annual Growth Rate (AGR) of 0.99%. The UK will have the highest number of diagnosed cases of CKD throughout the forecast period.

Scope

The Chronic Kidney Disease EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of chronic kidney disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

This report also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I–IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I–V, and the diagnosed prevalent cases of CKD by stage.

The chronic kidney disease epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Chronic Kidney Disease EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease treatment market.

Quantify patient populations in the chronic kidney disease market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chronic kidney disease therapeutics in each of the markets covered.

Understand magnitude of chronic kidney disease.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Chronic Kidney Disease: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for CKD (2016–2026)

3.5.1 Total Prevalent Cases of CKD, Stages I–IV

3.5.2 Age-Specific Total Prevalent Cases of CKD, Stages I–IV

3.5.3 Sex-Specific Total Prevalent Cases of CKD, Stages I–IV

3.5.4 Total Prevalent Cases of CKD by Stage

3.5.5 Diagnosed Prevalent Cases of CKD, Stages I–V

3.5.6 Diagnosed Prevalent Cases of CKD by Stage

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologists

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: KDIGO Classification of CKD

Table 2: Risk Factors and Comorbidities for CKD

Table 3: 7MM, Total Prevalent Cases of CKD, Stages I–IV, Both Sexes, Ages ≥20 Years, N, Selected Years from 2016–2026

Table 4: 7MM, Diagnosed Prevalent Cases of CKD, Stages I–V, Both Sexes, Ages ≥20 Years, N, Selected Years from 2016–2026

List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of CKD, Stages I–V, Both Sexes, Ages ≥20 Years, N, 2016 and 2026

Figure 2: 7MM, Age-Standardized Total Prevalence of CKD, Stages I–IV, Ages ≥20 Years, 2016

Figure 3: 7MM, Sources Used to Forecast the Total Prevalent Cases of CKD Stages I–IV

Figure 4: 7MM, Sources Used to Forecast the Total Prevalent Cases of CKD by Stage

Figure 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD Stages I–IV

Figure 6: 7MM, Sources Used to Forecast the Number of CKD Cases on Dialysis

Figure 7: 7MM, Sources Used to Forecast the Number of New Kidney Transplants

Figure 8: 7MM, Age-Specific Total Prevalent Cases of CKD, Stages I–IV, Both Sexes, Ages ≥20 Years, N, 2016

Figure 9: 7MM, Sex-Specific Total Prevalent Cases of CKD, Stages I–IV, Both Sexes, Ages ≥20 Years, N, 2016

Figure 10: 7MM, Total Prevalent Cases of CKD by Stage, Both Sexes, Ages ≥20 Years, N, 2016

Figure 11: 7MM, Diagnosed Prevalent Cases of CKD by Stage, Both Sexes, Ages ≥20 Years, N, 2016

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports